Biochemistry, Genetics and Molecular Biology
Amino Acids
16%
Apolipoprotein A1
9%
Blood Level
13%
Blood Plasma
10%
Data Analysis
13%
Diffusion Coefficient
5%
Dyslipidemia
41%
Facilitated Diffusion
16%
Fatty Acid-Binding Protein
13%
Genetic Association
13%
Genetic Divergence
8%
Glutamic Acid
9%
HDL-Cholesterol
7%
High-Density Lipoprotein
13%
Insulin Resistance
5%
Lipid
26%
Lipid Profile
5%
Lipoprotein
63%
Lipoprotein Blood Level
13%
Low Drug Dose
13%
Low-Density Lipoprotein
13%
Maturation
13%
Metabolite
39%
Metabolome
13%
Metabolomics
58%
Metabolomics
13%
Methionine
9%
Molecular Weight
12%
Normal Human
13%
Nuclear Magnetic Resonance Spectroscopy
49%
Omega 3 Fatty Acid
13%
PCSK9
13%
Pioglitazone
18%
Polyunsaturated Fatty Acid
10%
Principal Component Analysis
7%
Prospective Cohort Study
13%
Saturated Fat
13%
Saturated Fatty Acids
5%
Serum (Blood)
13%
Single Nucleotide Polymorphism
5%
Software
13%
Pharmacology, Toxicology and Pharmaceutical Science
Androgen
16%
Apolipoprotein A1
9%
Atomic Force Microscopy
13%
Azelaic Acid
5%
Cardiovascular Disease
11%
Cardiovascular Risk
11%
Cholesterol Ester
13%
Combination Therapy
13%
Diabetes Mellitus
15%
Disease Exacerbation
6%
Diseases
23%
Dyslipidemia
8%
Fenofibrate
13%
Fluorescent Dye
13%
Flutamide
18%
Glutamic Acid
9%
High Density Lipoprotein
15%
High Density Lipoprotein Cholesterol
16%
Human Study
13%
Impaired Glucose Tolerance
7%
Insulin Dependent Diabetes Mellitus
13%
Laropiprant Plus Nicotinic Acid
13%
Lipoprotein
100%
Low Density Lipoprotein
15%
Low Density Lipoprotein Cholesterol
6%
Metformin
13%
Methionine
9%
Non Insulin Dependent Diabetes Mellitus
18%
Nonessential Amino Acid
13%
Normal Human
13%
Omega-3 Fatty Acid
13%
Ovary Polycystic Disease
13%
Pharmacotherapy
13%
Pioglitazone
13%
Pistachio
13%
Placebo
6%
Plantago ovata
13%
Progestin
5%
Prospective Cohort Study
13%
Saturated Fatty Acid
21%
Simvastatin
13%
Triacylglycerol
36%
Very Low Density Lipoprotein
13%
Medicine and Dentistry
Analysis
13%
Androgen
16%
Apolipoprotein A1
9%
Atherosclerosis
5%
Azelaic Acid
5%
Biological Marker
5%
Combination Therapy
13%
Disease
13%
Dyslipidemia
16%
Flutamide
18%
Gestagen
5%
Glycon
13%
High-Density Lipoprotein
13%
Human Study
5%
Intima-Media Thickness
5%
Low Drug Dose
9%
Maturation
13%
Maturity Onset Diabetes of the Young
7%
Metabolic Syndrome
7%
Metabolomics
40%
Methionine
9%
NMR Spectroscopy
34%
Nutritional Intervention
13%
Pioglitazone
13%
Plantago ovata
13%
Polycystic Ovary Syndrome
13%
Protein Z
13%
Psychoacoustics
13%
Single Nucleotide Polymorphism
5%
Triacylglycerol
5%